The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 10, 2020

Filed:

Mar. 28, 2017
Applicant:

Gw Research Limited, Cambridge, GB;

Inventors:

Geoffrey Guy, Cambridge, GB;

Stephen Wright, Cambridge, GB;

Alice Mead, Cambridge, GB;

Anne Comi, Baltimore, MD (US);

Assignee:

GW RESEARCH LIMITED, Cambridge, GB;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/05 (2006.01); A61K 31/5513 (2006.01); A61K 31/4015 (2006.01); A61K 31/55 (2006.01); A61K 31/165 (2006.01); A61K 31/22 (2006.01); A61K 31/357 (2006.01); A61K 31/27 (2006.01); A61K 45/06 (2006.01); A61K 36/185 (2006.01); A61K 31/352 (2006.01); A61P 25/08 (2006.01);
U.S. Cl.
CPC ...
A61K 31/05 (2013.01); A61K 31/165 (2013.01); A61K 31/22 (2013.01); A61K 31/27 (2013.01); A61K 31/352 (2013.01); A61K 31/357 (2013.01); A61K 31/4015 (2013.01); A61K 31/55 (2013.01); A61K 31/5513 (2013.01); A61K 36/185 (2013.01); A61K 45/06 (2013.01); A61P 25/08 (2018.01);
Abstract

The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD appears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract ofsuch that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.


Find Patent Forward Citations

Loading…